Evidence map›Paper›PMID 31117311›Full record

ReviewInternational journal of molecular sciences2019

Updates on Aptamer Research.

Mohamed H Ali, Marwa E Elsherbiny, Marwan Emara

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 179 citations in OpenAlex.

  1. Article
  2. Cu-MOF-NHMikrochimica acta · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Aptamers: precision tools for diagnosing and treating infectious diseases.Frontiers in cellular and infection microbiology · 2024
    Review
  19. Review
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Mohamed H AliCenter for Aging and Associated Diseases, Zewail City of Science and Technology, Giza 12578, Egypt. mali@zewailcity.edu.eg.
Marwa E ElsherbinyDepartment of Pharmacology and Toxicology, Ahram Canadian University, 6th of October City, Giza 12566, Egypt. marwae@ualberta.ca.
Marwan EmaraCenter for Aging and Associated Diseases, Zewail City of Science and Technology, Giza 12578, Egypt. memara@zewailcity.edu.eg.
Zewail City of Science and Technology · EGAhram Canadian University · EG

Funding

Science and Technology Development Fund 15193
6 · The paper itself

Abstract

For many years, different probing techniques have mainly relied on antibodies for molecular recognition. However, with the discovery of aptamers, this has changed. The science community is currently considering using aptamers in molecular targeting studies because of the many potential advantages they have over traditional antibodies. Some of these possible advantages are their specificity, higher binding affinity, better target discrimination, minimized batch-to-batch variation, and reduced side effects. Overall, these characteristics of aptamers have attracted scholars to use them as molecular probes in place of antibodies, with some aptamer-based targeting products being now available in the market. The present review is aimed at discussing the potential of aptamers as probes in molecular biology and in super-resolution microscopy.

Indexed as

Aptamers, NucleotideAntibodiesSELEX Aptamer TechniqueAntibodiesAptamers, NucleotideantibodiesaptamernanobodiesSELEXsuper-resolution microscopy

Identifiers

PMID31117311
PMCPMC6566374
OpenAlexW2945985499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.